FAQ

Evangelos Briasoulis

Suggest Changes
Georgios Fountzilas86
Nikolas Pavlidis60
Paris A Kosmidis52
Dimitrios Bafaloukos46
D V Skarlos41
114Georgios Fountzilas
61Dimitrios Pectasides
57Nikolas Pavlidis
55Meletios-Athanassios Dimopoulos
55Dimitrios Bafaloukos

Filter Results:

  • Full text PDF available (34)

Publication Year

1994
2017
  • This year (2)
  • Last 5 years (28)
  • Last 10 years (69)

Publication Type

Co-author

Journals and Conferences

Learn More
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted…
PURPOSE The aim of this study was to explore the effect of dose-dense sequential chemotherapy with or without paclitaxel primarily on disease-free survival (DFS) and secondarily on overall survival… (More)
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized…
BACKGROUND A randomized phase III trial in high-risk breast cancer patients was conducted, to further explore the impact of dose-density in the adjuvant treatment for breast cancer. The safety… (More)
‘Classical' but not ‘other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
‘Classical’ mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21) have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC. The aim of the… (More)